Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51
NCT ID: NCT00594958
Last Updated: 2024-03-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
639 participants
INTERVENTIONAL
2006-09-30
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51
NCT00595465
Immunogenicity Study of the Japanese Encephalitis Vaccine IC51
NCT00604708
Safety and Tolerability of the Japanese Encephalitis Vaccine IC51
NCT00605085
Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51
NCT00595790
Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51
NCT00596102
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
624 subjects will be enrolled at approximately 6 sites in study centers in Austria and Germany.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IC51 Group A
IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
IC51
6 mcg, intramuscularly \[i.m.\], 0.5 mL
IC51 Group B
IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
IC51
6 mcg, intramuscularly \[i.m.\], 0.5 mL
IC51 Group C
IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
IC51
6 mcg, intramuscularly \[i.m.\], 0.5 mL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IC51
6 mcg, intramuscularly \[i.m.\], 0.5 mL
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Valneva Austria GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Susanne Eder, Mag.
Role: STUDY_DIRECTOR
Valneva Austria GmbH
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IC51-309
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.